Regulatory FDA’s ODAC delivers one loss, one win for AstraZeneca PharmaphorumThe FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.OncologyRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaphorum The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitationNext: Amgen positions MariTide as potential ‘best monthly’ obesity drug Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
